Rethinking Cervical Cancer Screening: - SkyArch Medical Clinic Brisbane

The HPV PCR–Based Screening Program Implemented in Australia

HPV PCR as the Standard for Cervical Cancer Screening in Advanced Countries

— Scientific Evidence Shared by WHO, Australia, the UK, and the Netherlands —

HPV PCR–based testing (HPV DNA testing), which directly detects high-risk human papillomavirus—the causal agent of cervical cancer—has higher sensitivity than cytology (Pap smear), allows screening intervals to be safely extended, and is the most appropriate screening method in the era of HPV vaccination.

This understanding is now fully shared among advanced countries, including the World Health Organization (WHO), Australia, the United Kingdom, and the Netherlands.

1️⃣ HPV PCR Detects the Cause of Disease

Almost 100% of cervical cancers are caused by persistent infection with high-risk HPV.

HPV PCR testing:

Directly detects high-risk HPV DNA
Identifies cancer risk before cytological abnormalities appear

As a result, HPV PCR has been shown to have significantly higher sensitivity than cytology for detecting CIN2+ and CIN3+ lesions.

The World Health Organization (WHO) recommends HPV DNA testing as the primary method for cervical cancer screening.

2️⃣ High Sensitivity Allows Safe 5-Year Screening Intervals

When an HPV PCR result is negative, the risk of developing cervical cancer over the following several years is extremely low.

Therefore, advanced countries have adopted scientifically rational screening designs:

Screening interval: every 5 years
Starting age: 25–30 years and older

3️⃣ Cytology Has Shifted from Primary Screening to Triage

The current model used by advanced countries follows a common pathway:

HPV PCR (primary screening)
→ Cytology only if HPV is positive (triage)
→ Colposcopy based on risk assessment

This approach achieves:

Reduced false-negative results
Fewer unnecessary investigations
More efficient use of healthcare resources

4️⃣ Optimal for the HPV Vaccination Era

As HPV vaccination coverage increases:

Cytological abnormalities become less common
The efficiency of cytology-based screening declines

HPV PCR remains effective even in low-prevalence populations and is positioned as the core screening method for future generations, including vaccinated cohorts.

5️⃣ Enables Self-Sampling

One major advantage of HPV PCR testing is its suitability for self-collected samples.

This leads to:

Increased screening participation
Reduced geographic and psychological barriers
Significant public health benefits

This feature is particularly emphasized in Australia and the Netherlands.

National Policy Positions

WHO

Clearly recommends HPV DNA testing as the primary screening method for cervical cancer
Demonstrates higher sensitivity than cytology or VIA

Australia

Nationwide implementation of HPV PCR as the primary screening test since 2017
Target population: ages 25–74, screened every 5 years
Self-collection formally incorporated into the program

United Kingdom (UK)

HPV-based primary screening under the NHS Cervical Screening Programme
HPV-negative → rescreen in 5 years
Cytology used only for HPV-positive cases (triage)

Netherlands

One of the earliest countries to fully transition to nationwide HPV PCR primary screening in 2017
The national program is managed by RIVM (National Institute for Public Health and the Environment)
Self-sampling HPV testing is formally integrated
Internationally recognized for high participation rates, cost-effectiveness, and early detection of CIN3+

The Netherlands represents a fully realized model of
“HPV PCR + self-sampling + 5-year screening intervals”,
which has significantly influenced WHO recommendations and policy development in other countries.

Implications for Japan (Summary)

HPV PCR screening has not been adopted simply because it is “advanced,” but because it fulfills all key requirements: